Harveer Dev

1.2k total citations
20 papers, 363 citations indexed

About

Harveer Dev is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Harveer Dev has authored 20 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Harveer Dev's work include Prostate Cancer Diagnosis and Treatment (6 papers), Prostate Cancer Treatment and Research (5 papers) and Urinary Tract Infections Management (4 papers). Harveer Dev is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (6 papers), Prostate Cancer Treatment and Research (5 papers) and Urinary Tract Infections Management (4 papers). Harveer Dev collaborates with scholars based in United Kingdom, United States and Australia. Harveer Dev's co-authors include Prasanna Sooriakumaran, Samih Al‐Hayek, Nathan Lawrentschuk, Nathan Papa, Sani H. Aliyu, David E. Neal, Ashutosh Tewari, Thomas E. Ahlering, Nimish Shah and Douglas Skarecky and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and The Journal of Urology.

In The Last Decade

Harveer Dev

18 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harveer Dev United Kingdom 12 183 103 77 64 57 20 363
Ofer Nativ Israel 9 64 0.3× 115 1.1× 51 0.7× 21 0.3× 41 0.7× 31 262
A Hofstetter Germany 7 95 0.5× 208 2.0× 65 0.8× 58 0.9× 94 1.6× 44 377
Saoussen Abroug Tunisia 10 108 0.6× 47 0.5× 14 0.2× 79 1.2× 30 0.5× 49 280
Kyril B. Conger United States 9 63 0.3× 108 1.0× 46 0.6× 46 0.7× 21 0.4× 16 272
Kojiro Honda Japan 12 153 0.8× 52 0.5× 26 0.3× 49 0.8× 64 1.1× 33 363
Koen van Aerde Netherlands 7 35 0.2× 85 0.8× 22 0.3× 133 2.1× 44 0.8× 22 255
Yong Gon Cho South Korea 11 44 0.2× 12 0.1× 24 0.3× 67 1.0× 47 0.8× 50 284
Rebecca F. Geddes United Kingdom 11 66 0.4× 86 0.8× 24 0.3× 50 0.8× 12 0.2× 34 436
Takanori Ochi Japan 12 117 0.6× 359 3.5× 100 1.3× 71 1.1× 23 0.4× 77 517
Imran Nizami Saudi Arabia 11 149 0.8× 47 0.5× 11 0.1× 46 0.7× 57 1.0× 25 273

Countries citing papers authored by Harveer Dev

Since Specialization
Citations

This map shows the geographic impact of Harveer Dev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harveer Dev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harveer Dev more than expected).

Fields of papers citing papers by Harveer Dev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harveer Dev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harveer Dev. The network helps show where Harveer Dev may publish in the future.

Co-authorship network of co-authors of Harveer Dev

This figure shows the co-authorship network connecting the top 25 collaborators of Harveer Dev. A scholar is included among the top collaborators of Harveer Dev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harveer Dev. Harveer Dev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Illuzzi, Giuditta, Alessandro Galbiati, Anna D. Staniszewska, et al.. (2025). Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair. NAR Cancer. 7(4). zcaf035–zcaf035.
2.
Lleshi, Ermira, Robert L. Hanson, Radosław Lach, et al.. (2024). Prostate cancer detection through unbiased capture of methylated cell-free DNA. iScience. 27(7). 110330–110330. 5 indexed citations
3.
4.
Lloyd, Paul, Anne Hong, Marc A. Furrer, et al.. (2021). A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World Journal of Urology. 40(1). 119–126. 22 indexed citations
5.
Pacey, Simon, Mark Linch, Howard Kynaston, et al.. (2019). A study into the pharmacodynamic biomarker effects of olaparib (PARP Inhibitor) ± degarelix (GnRH antagonist) given prior to radical prostatectomy (RP) CANCAP03.. Journal of Clinical Oncology. 37(7_suppl). 35–35. 2 indexed citations
6.
Papa, Nathan, Marlon Perera, Sani H. Aliyu, et al.. (2017). Staphylococcus aureus urinary tract bacteriuria: single-institutional antibiotic susceptibility trends over a decade. 4(3). 1–1. 2 indexed citations
7.
Dev, Harveer, Stephanie Poo, James A. Armitage, et al.. (2016). Investigating upper urinary tract urothelial carcinomas: a single-centre 10-year experience. World Journal of Urology. 35(1). 131–138. 24 indexed citations
8.
Sooriakumaran, Prasanna, Harveer Dev, Douglas Skarecky, & Thomas E. Ahlering. (2016). The importance of surgical margins in prostate cancer. Journal of Surgical Oncology. 113(3). 310–315. 33 indexed citations
9.
10.
Papa, Nathan, et al.. (2016). Vancomycin resistant enterococci in urine cultures: Antibiotic susceptibility trends over a decade at a tertiary hospital in the United Kingdom. Investigative and Clinical Urology. 57(2). 129–129. 28 indexed citations
11.
12.
Papa, Nathan, et al.. (2015). Candidagrowth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. QJM. 109(5). 325–329. 13 indexed citations
13.
Dev, Harveer, Peter Wiklund, Vipul Patel, et al.. (2014). Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urologic Oncology Seminars and Original Investigations. 33(3). 109.e7–109.e13. 66 indexed citations
14.
Dev, Harveer, Prasanna Sooriakumaran, Abhishek Srivastava, & Ashutosh Tewari. (2012). Optimizing radical prostatectomy for the early recovery of urinary continence. Nature Reviews Urology. 9(4). 189–195. 18 indexed citations
15.
Dev, Harveer, Naomi L. Sharma, Sarah Dawson, David E. Neal, & Nimish Shah. (2011). Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. British Journal of Urology. 109(7). 1074–1080. 18 indexed citations
16.
Dev, Harveer, David S. Rickman, Prasanna Sooriakumaran, et al.. (2011). Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies. Journal of Translational Medicine. 9(1). 121–121. 22 indexed citations
17.
Dev, Harveer, Prasanna Sooriakumaran, Jens‐Uwe Stolzenburg, & Christopher J. Anderson. (2011). Is robotic technology facilitating the minimally invasive approach to partial nephrectomy?. British Journal of Urology. 109(5). 760–768. 15 indexed citations
18.
Srivastava, Abhishek, Prasanna Sooriakumaran, Sonal Grover, et al.. (2011). Pathological outcomes and strategies to achieve optimal cancer control during robotic radical prostatectomy in Asian-Indian men. Indian Journal of Urology. 27(3). 326–326. 11 indexed citations
19.
Dev, Harveer, Prasanna Sooriakumaran, Ashutosh Tewari, & Abhay Rané. (2010). LESSons in minimally invasive urology. British Journal of Urology. 107(10). 1555–1559. 10 indexed citations
20.
Dev, Harveer, Andrew P. Stewart, Nelson P. Barrera, et al.. (2008). Direct visualization of the trimeric structure of the ASIC1a channel, using AFM imaging. Biochemical and Biophysical Research Communications. 372(4). 752–755. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ofer Nativ Breakdown of academic impact, for papers by A Hofstetter Breakdown of academic impact, for papers by Saoussen Abroug Breakdown of academic impact, for papers by Kyril B. Conger Breakdown of academic impact, for papers by Kojiro Honda Breakdown of academic impact, for papers by Koen van Aerde Breakdown of academic impact, for papers by Yong Gon Cho Breakdown of academic impact, for papers by Rebecca F. Geddes Breakdown of academic impact, for papers by Takanori Ochi Breakdown of academic impact, for papers by Imran Nizami
Rankless by CCL
2026